About us

The Monoclonal Antibody Core Facillity at the Helmholtz Zentrum München (formerly GSF) was founded in 1990 by Dr. Elisabeth Kremmer. During the past 25 years, the Core Facility acquired profound expertise and established antibodies against more than 2000 targets.

To meet the constantly rising demand for custom-made monoclonal antibodies during the past years, we updated the workflow, minimized the numbers of required animals through multi-immunization protocols and introduced advanced automated liquid handling technology to allow high-throughput screening. Currently we are generating more than 100 new antibodies per year, ranging from antibodies against small molecules such as pesticides to cell surface receptors.

Monoclonal antibodies are a very valuable asset for many research projects not only within the Helmholtz Zentrum München. We are not only providing a service in generating new antibodies but also collaborate with scientists in developing new antibody-based technologies. We closely collaborate with the Munich Universities LMU and TU, Max-Planck Institutes and other partner Institutions in the Munich area, but also throughout Germany and the world. The Monoclonal Antibody Core Facillity is part of several collaborative research efforts such as DFG-funded Collaborative Research Centers and Priority Programs (SPP 1784), the SyNergy Excellence Cluster as well as the German Center for Neurodegenerative Diseases (DZNE).

We use cookies to improve your experience on our Website. We need cookies to continuously improve the services, to enable certain features and when embedding services or content of third parties, such as video player. By using our website, you agree to the use of cookies. We use different types of cookies. You can personalize your cookie settings here:

Show detail settings
Please find more information in our privacy statement.

There you may also change your settings later.